Thx Dew. I have a position in FATE and will do some DD on BEAM
Those I knew in the field had concerns about off target affects ....but maybe they ( BEAM ? ) have overcome / reduced those risks . FATE seems focused on Oncology applications and CRSP on sickle cell ... from memory .
Dew ... I’m not an MD .. just by accident ( soccer moms / dads etc ) know people working in this area in SF / Silicon Valley Biotech Kiwi